×
About 3,068 results

ALLMedicine™ Hyperhidrosis Center

Research & Reviews  864 results

Treatment of Hyperhidrosis: An Update.
https://doi.org/10.1007/s40257-022-00707-x 10.1016/j.jaad.2003.12.029 10.1097/00029330-200712020-00011 10.1016/j.ejcts.2007.01.020 10.1371/journal.pone.0092412 10.1016/j.det.2015.07.003 10.1159/000486713 10.1097/01.pra.0000452570.69578.31 10.1016/j.jaad.2016.07.001 10.1016/j.jaad.2009.02.038 10.1007/s00403-016-1697-9 10.1007/s00266-021-02140-7 10.1002/lsm.23229 10.1111/bjd.15808 10.1111/bjd.16558 10.1007/s40257-018-0395-0 10.1016/j.jaad.2018.07.002 10.1111/1346-8138.15927 10.2147/CCID.S210973 10.1097/DSS.0000000000001532 10.1111/j.1524-4725.2011.02250.x 10.1002/lsm.22324 10.1111/ajd.12260 10.1111/j.1365-2133.2011.10786.x 10.1111/dth.14354 10.1007/s00105-009-1841-y 10.1111/bjd.19810 10.1111/jdv.12518 10.1111/pde.13723 10.1007/s40257-019-00446-6 10.1111/pde.14135 10.1111/1346-8138.16188 10.1016/j.jaad.2020.02.016 10.1111/1346-8138.15668 10.2340/00015555-2731 10.1111/1346-8138.13748 10.1080/09546634.2019.1569751 10.1111/dsu.12099 10.1111/j.1440-0960.2004.00098.x 10.1111/j.1346-8138.2003.tb00414.x 10.1016/j.mjafi.2014.01.008 10.3109/09546634.2012.739679 10.1111/j.1468-3083.2011.04197.x 10.1111/pde.12620 10.1111/1346-8138.15029 10.1111/j.1524-4725.2009.01140.x 10.1016/j.athoracsur.2004.02.087 10.1111/jocd.12049 10.1016/j.ejcts.2008.03.033 10.1097/01.DSS.0000452649.99141.69 10.1007/s10103-020-03064-5 10.1097/DSS.0000000000002901 10.1111/bjd.16781 10.1016/j.jvs.2011.12.039 10.1111/bjd.13973 10.1111/pde.12142 10.1007/s10286-014-0264-8 10.1016/j.avsg.2013.12.024 10.1002/lsm.23073 10.1007/s10103-020-02958-8 10.2340/00015555-3790 10.1097/GOX.0000000000004172 10.1007/s41649-020-00145-z
American Journal of Clinical Dermatology; Henning MAS, Bouazzi D et. al.

Jul 1st, 2022 - Hyperhidrosis is a dermatosis presenting as pathologically excessive focal or generalized sweating. The stigmatizing nature of hyperhidrosis may cause patients to feel embarrassment and apprehension about their symptoms and experience a significan...

Questionnaire-based epidemiological survey of primary focal hyperhidrosis and survey on...
https://doi.org/10.1007/s00403-022-02365-9 10.1159/000351292 10.1016/j.jaad.2016.07.001 10.1007/s00403-016-1697-9 10.1111/1346-8138.12258 10.1159/000092285 10.1016/j.jaad.2003.12.029 10.1186/s12955-017-0693-x 10.1007/s11136-014-0825-2 10.1371/journal.pone.0153719 10.1186/s41687-019-0148-8 10.1007/s40257-018-0395-0 10.1159/000448032 10.1111/j.1524-4725.2007.33192.x 10.1016/j.jaad.2003.12.040
Archives of Dermatological Research; Fujimoto T, Inose Y et. al.

Jun 30th, 2022 - To obtain current epidemiological information on primary focal hyperhidrosis in Japan, a large epidemiological survey was conducted using a web-based questionnaire. The prevalence of primary focal hyperhidrosis was 10.0% and the site-specific prev...

Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri inte...
https://doi.org/10.1186/s13256-022-03479-4 10.1111/eos.12536 10.1097/BOR.0000000000000622 10.1038/s41467-021-23472-7 10.2165/00003495-200868120-00006 10.1007/978-3-319-43806-1_2 10.1089/rej.2013.1431 10.1016/0197-4580(87)90034-0 10.1007/s13181-010-0112-8 10.3390/molecules19022588 10.1002/cpt.2350 10.1053/j.ackd.2019.08.003 10.1016/S0002-9343(97)00397-5 10.1089/acm.2008.0290 10.1370/afm.947
Journal of Medical Case Reports; Acquarulo B, Tandon P et. al.

Jun 29th, 2022 - Muscarinic agonists are indicated for the treatment of many conditions including ileus, urinary retention, glaucoma, and Sjögren's syndrome. Due to their lack of tissue specificity, these drugs can lead to undesirable side effects at off-target si...

Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in a subject affected by Sh...
https://doi.org/10.1080/21645515.2022.2094148
Human Vaccines & Immunotherapeutics; Moscara L, Tafuri S et. al.

Jun 29th, 2022 - Shapiro's syndrome (SS) is a rare neurological disorder characterized by spontaneous periodic hypothermia and hyperhidrosis without identifiable systemic causes or brain injuries. We present the case of F. a young patient, without agenesis of the ...

The temporal association of hyperhidrosis and its co-morbidities - a nationwide hospita...
https://doi.org/10.1111/jdv.18351
Journal of the European Academy of Dermatology and Venere... Henning M, Reguant R et. al.

Jun 24th, 2022 - Research on hyperhidrosis comorbidities has documented the co-occurrence of diseases but has not provided information about temporal disease associations. To investigate the temporal disease trajectories of individuals with hospital diagnosed hype...

see more →

Drugs  72 results see all →

Clinicaltrials.gov  107 results

Assessment of Efficacy and Safety of Topical Administration of 1% Glycopyrronium Bromide (GPB) in Patients With Primary Axillary Hyperhidrosis and the Assessment of Long-term Efficacy and Safety of...
https://clinicaltrials.gov/ct2/show/NCT03658616

Mar 18th, 2022 - The aim of this study is to investigate the efficacy and safety of 1% GPB cream after 4 weeks of treatment compared with placebo with a sufficient number of patients to obtain statistically significant results, and to assess the long-term safety o...

Longevity of Microwave Thermolysis and Botulinum Toxin A for Treatment of Axillary Hyperhidrosis
https://clinicaltrials.gov/ct2/show/NCT05057117

Mar 2nd, 2022 - This trial aims is to assess and compare treatment effect of microwave thermolysis and botulinum toxin A for axillary hyperhidrosis with focus on longevity. The investigators also aim to assess patient satisfaction and adverse reactions in relatio...

Qbrexza Cloths for Hyperhidrosis of Amputation Sites
https://clinicaltrials.gov/ct2/show/NCT04924036

Feb 10th, 2022 - BACKGROUND: Approximately 1 in 190 people in the United States have experienced a limb amputation. Of these patients with amputations, over sixty percent suffer from hyperhidrosis at the amputation site. Amputation site hyperhidrosis interferes wi...

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
https://clinicaltrials.gov/ct2/show/NCT03836287

Jan 25th, 2022 - This is a multicenter, randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of topically applied sofpironium bromide, 15% gel in subjects with axillary hyperhidrosis. Safety will be assessed through collection of ...

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
https://clinicaltrials.gov/ct2/show/NCT03948646

Jan 25th, 2022 - This is a multicenter, randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of topically applied sofpironium bromide, 15% gel in subjects with axillary hyperhidrosis. Safety will be assessed through collection of ...

see more →

News  180 results

Adhesive Tape to Guide Injection Depth of Botulinum Toxin for Axillary Hyperhidrosis
https://www.mdedge.com/dermatology/article/255261/aesthetic-dermatology/adhesive-tape-guide-injection-depth-botulinum-toxin
Jamison A. Harvey, MD, David L. Swanson, MD

Jun 7th, 2022 - Practice Gap OnabotulinumtoxinA is a US Food and Drug Administration–approved second-line treatment of axillary hyperhidrosis, with a long-term success rate greater than 80% and minimal adverse effects. 1 The recommended depth and angle of injectio.

What’s ahead for laser-assisted drug delivery?
https://www.mdedge.com/dermatology/article/255160/dermatologic-surgery/whats-ahead-laser-assisted-drug-delivery
Doug Brunk

Jun 2nd, 2022 - SAN DIEGO – Twelve years ago, Merete Haedersdal, MD, PhD, and colleagues published data from a swine study, which showed for the first time that the ablative fractional laser can be used to boost the uptake of drugs into the skin. That discovery p.

Botulinum toxin for chronic pain: What's on the horizon?
https://www.mdedge.com/familymedicine/article/248633/musculoskeletal-disorders/botulinum-toxin-chronic-pain-whats-horizon
MDedge Family Medicine; Caleb Dickison, DO, CAQSM, Jeffrey C. Leggit, MD, CAQSM

Nov 12th, 2021 - Botulinum toxin (BoNT) was first approved by the US Food and Drug Administration (FDA) for the treatment of strabismus and blepharospasm in 1989. Since then, approved indications have expanded to include spasticity, cervical dystonia, severe axill.

Multiple Features Help Distinguish Hyperhidrosis From Normal Sweating
https://www.medscape.com/viewarticle/962552

Nov 9th, 2021 - LOS ANGELES — When Adam Friedman, MD, establishes a diagnosis of hyperhidrosis with patients and informs them that it's a medical condition, sometimes they break down in tears. Dr Adam Friedman "That's because for years they may have been thinking...

Teen boy’s knee lesion has changed
https://www.mdedge.com/pediatrics/article/247654/dermatology/teen-boys-knee-lesion-has-changed
Catalina Matiz, MD

Oct 20th, 2021 - A biopsy of the lesion was performed which showed an increased number of eccrine glands and blood vessels within the dermis. Some areas showed an increase in adipocytes and smooth muscle bundles.

see more →

Patient Education  4 results see all →